Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Quantumup Feb. 24 at 1:24 PM

Oppenheimer reiterated $ORIC Outperform/$15, and said, ORIC reported fourth quarter and full year 2025 results that support what increasingly feels like a two-shots-on-goal story. $PFE $JNJ TAK AZN NVS $AVBP $BDTX Rinzimetostat continues to look competitive in mCRPC with 55% PSA50, 20% PSA90, and 59% ctDNA clearance, and has now moved into dose optimization ahead of a planned 1H26 Phase 3 start. While Pfizer's upcoming MEVPRO-1 readout will be a pivotal moment for the PRC2 class, we believe rinzi can differentiate on safety and PK. In parallel, enozertinib's exon 20 and PACC data has demonstrated systemic activity and compelling CNS control, with the Phase 3 monotherapy dose selected and combo with subcutaneous amivantamab progressing. We will be hosting ORIC management for a fireside chat during our Healthcare Conference on Wednesday, February 25th at 12:00 PM EST. Reiterate Outperform.

0 · Reply

Whitaker1997 Feb. 24 at 8:01 AM

$JNJ trending near highs with $246.9 as recent HOD Orderflow looks absorbed, no real breakout yet

0 · Reply

TradeWoFear Feb. 24 at 7:59 AM

$JNJ watch out... by CNN business !! i will leave the last guess to you!!

0 · Reply

itsallaboutheoptions Feb. 24 at 7:43 AM

$JNJ $UPS learn the correct interpretation

0 · Reply

DragonAlgo Feb. 24 at 7:33 AM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-02-27 | Strike: $245.00 | Type: CALL Option Plan (premium): Entry: $2.30 Stop: $1.66 TP1: $2.99 TP2: $3.91 TP3: $5.52 🔗 https://dragonalgo.com

0 · Reply

SquawkAlley Feb. 24 at 7:02 AM

$LLYX.X $GRPN $JNJ BULLISH Eli Lilly Unveils Once-Monthly Zepbound Pen, Slashing Injection Burden for Weight Loss Patients CWEB Business News https://cweb.com/eli-lilly-unveils-once-monthly-zepbound-pen-slashing-injection-burden-for-weight-loss-patients-cweb-business-news/

0 · Reply

TheHumanAlgo Feb. 24 at 12:37 AM

$JNJ Today was actually a gift for put buyers. Bought puts at the close.

0 · Reply

Ro_Patel Feb. 23 at 11:51 PM

Today's option volume of 63.9M contracts was -8.00% below recent average levels, w/ calls leading puts 5 to 4 ETF & index products saw relatively heavy volume, while single stock flow was moderate Today's most active sectors included Health Care, Consumer Cyclicals, & Utilities, while Financials & Telecommunications were relatively light Among the 500 most liquid single stocks, 30day IV was higher for 423 & lower for 24 Unusual total option volume was observed in $JNJ $NVO $IBRX $CRWD & $OWL

0 · Reply

QuantInsider Feb. 23 at 11:39 PM

Big moves on $JNJ today Around 3:52 PM, a massive cluster of deep-in-the-money March calls hit with 58k contracts and $361M in premium No offsetting puts, just pure bullish vibes 98% of recent options premium is on the call side Price is only up about 1% but this flow suggests upside participation Mostly 25-day blocks hinting at institutional moves, not fast trades If you're tracking this, think multi-week strategy

1 · Reply

stockwatcherking Feb. 23 at 9:03 PM

$JNJ Wow that is ALOT of call selling. Extreme levels. They getting ready to pull this back and take profits.

1 · Reply

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 21 hours ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 22 hours ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 3 days ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:30 PM EST - 4 days ago

Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)

Feb 19, 2026, 5:00 PM EST - 4 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 4 days ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 4 days ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 9:15 AM EST - 4 days ago

2 High-Yield CEFs To Enhance Your Retirement Income

AMLP ASGI BIZD BTI MO SCHD T

Feb 18, 2026, 10:44 AM EST - 5 days ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 5 days ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 5 days ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 6 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 7 days ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 6:23 AM EST - 7 days ago

Dividend Income: Lanny's December 2025 Summary

ADM AFL EMR GWW IBM LYB MCD

Feb 13, 2026, 4:19 PM EST - 10 days ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 10 days ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 2:43 PM EST - 10 days ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 7:00 AM EST - 11 days ago

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 11, 2026, 2:23 PM EST - 12 days ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 9, 2026, 4:16 PM EST - 14 days ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 17 days ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 18 days ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 19 days ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 20 days ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 21 days ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 21 days ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 1, 2026, 10:35 AM EST - 22 days ago

Ariel Focus Fund Q4 2025 Portfolio Review

ADT AMG B FISV MOS ORCL

Jan 30, 2026, 2:43 PM EST - 24 days ago

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

Jan 30, 2026, 7:19 AM EST - 25 days ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 29, 2026, 6:32 PM EST - 25 days ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 12:42 PM EST - 25 days ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Jan 28, 2026, 9:38 AM EST - 26 days ago

Johnson & Johnson: Strong Momentum Heading Into 2026

Jan 27, 2026, 3:49 PM EST - 27 days ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 8:00 AM EST - 4 weeks ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

Jan 25, 2026, 10:11 PM EST - 4 weeks ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BDX

Jan 22, 2026, 12:15 AM EST - 4 weeks ago

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 21, 2026, 11:20 PM EST - 4 weeks ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 6:45 PM EST - 4 weeks ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Jan 21, 2026, 1:56 PM EST - 4 weeks ago

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 12:15 PM EST - 4 weeks ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 10:00 AM EST - 4 weeks ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

Jan 21, 2026, 7:26 AM EST - 4 weeks ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 6:23 AM EST - 4 weeks ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:20 AM EST - 4 weeks ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 4 weeks ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 1:07 AM EST - 4 weeks ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 20, 2026, 8:37 AM EST - 4 weeks ago

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Jan 19, 2026, 8:00 AM EST - 5 weeks ago

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Jan 19, 2026, 5:08 AM EST - 5 weeks ago

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

Quantumup Feb. 24 at 1:24 PM

0 · Reply

Whitaker1997 Feb. 24 at 8:01 AM

$JNJ trending near highs with $246.9 as recent HOD Orderflow looks absorbed, no real breakout yet

0 · Reply

TradeWoFear Feb. 24 at 7:59 AM

$JNJ watch out... by CNN business !! i will leave the last guess to you!!

0 · Reply

itsallaboutheoptions Feb. 24 at 7:43 AM

$JNJ $UPS learn the correct interpretation

0 · Reply

DragonAlgo Feb. 24 at 7:33 AM

0 · Reply

SquawkAlley Feb. 24 at 7:02 AM

0 · Reply

TheHumanAlgo Feb. 24 at 12:37 AM

$JNJ Today was actually a gift for put buyers. Bought puts at the close.

0 · Reply

Ro_Patel Feb. 23 at 11:51 PM

0 · Reply

QuantInsider Feb. 23 at 11:39 PM

1 · Reply

stockwatcherking Feb. 23 at 9:03 PM

$JNJ Wow that is ALOT of call selling. Extreme levels. They getting ready to pull this back and take profits.

1 · Reply

tylerrubin337 Feb. 23 at 8:41 PM

$JNJ swinging bullish

0 · Reply

KingTrades09 Feb. 23 at 5:48 PM

$JNJ no profit taking yet as dividend day is tomorrow. I expect a pullback to 225-230 in a week or two. Holding 240 puts

0 · Reply

HollywoodWolf007 Feb. 23 at 5:39 PM

-$40 you actually think you can hide in here $JNJ POS you shit

0 · Reply

HollywoodWolf007 Feb. 23 at 5:16 PM

$JNJ

1 · Reply

wwmeinc Feb. 23 at 4:46 PM

$VKTX $NVO $LLY $JNJ $ABBV ......With a headline leading with "obsolete"....hmmm.....billions and billions now hanging on NVO's next move...big bucks to the C-suite holder for just these kinds of decision making 'duties'.....talk about having the spotlight of the drug world on them...guessing NVO is not feeling the heat ;) Not! glta "Søren Løntoft Hansen, a senior analyst at Denmark’s AL Sydbank, said: “This is something of a swing and a miss.” He added: “It is difficult to assess whether this data will influence Novo Nordisk’s decision to launch CagriSema on the market.”" https://www.theguardian.com/business/2026/feb/23/wegovy-ozempic-weight-loss-drug-novo-nordisk-cagrisema

0 · Reply